A new study analyzing insurance claims data for nearly 870,000 Oregon adolescents has found that medical interventions among youth identifying as transgender have increased substantially over recent years, fueling an ongoing debate about how policymakers and advocates interpret pediatric gender medicine statistics.
The research, published in Research Connections and reported by Benjamin Ryan, examined insurance claims for 868,740 insured Oregonians ages 8 to 17 from 2016 to 2023. The data cover roughly 80 percent of all insured youth in the state. Researchers found that by age 17, approximately one in 240 insured Oregon girls was taking testosterone, and about one in 630 boys was taking estrogen. Across all ages studied, roughly 1 percent of insured Oregon youth had received a gender-related diagnosis; for girls alone, the figure reached 1.5 percent.
Oregon is considered an unusually supportive legal and insurance environment for pediatric gender medicine compared to other states. The study's authors noted that access remains limited even in Oregon and suggested structural barriers may still be holding treatment rates down relative to potential demand.
What the Right Is Saying
Critics of expanded pediatric gender medicine argue that the rising Oregon figures illustrate the risks of loosening oversight of cross-sex hormone prescriptions for minors. Conservative analysts contend that the framing of any data outcome as evidence supporting affirmation—regardless of whether rates are high or low, rising or stable—represents circular reasoning rather than scientific rigor.
Kenneth Zucker, a leading expert on childhood gender dysphoria, has argued that social transition itself is not a neutral intervention and may influence whether children's cross-sex identities persist into adolescence when medical interventions become available. Conservative critics argue this raises concerns about iatrogenic effects—outcomes caused by the treatments themselves rather than underlying conditions.
Some Republican legislators in other states have pointed to studies like Oregon's as justification for age-based restrictions on pediatric gender medicine, arguing that the lack of long-term outcome data from randomized trials warrants caution before minors receive irreversible interventions. They contend that 17-year-olds should not be accessing testosterone or estrogen without more extensive safeguards and longitudinal research.
What the Left Is Saying
Progressives and advocates for transgender youth argue that the Oregon data reflects a positive trend toward reducing stigma and expanding access to evidence-based care. They contend that years of political opposition and legal restrictions have prevented many young people from accessing treatments that major medical organizations, including the American Academy of Pediatrics, support as appropriate for carefully assessed patients with gender dysphoria.
Transgender rights advocates note that even the elevated figures represent a small percentage of the overall adolescent population. Ari Drennen, a trans activist quoted on social media, argued that the rates should not be considered alarming given the total number of insured youth in the study. Supporters emphasize that puberty blockers and cross-sex hormones have been shown to reduce psychological distress when prescribed following established clinical guidelines.
Medical organizations including WPATH (the World Professional Association for Transgender Health) maintain that access to gender-affirming care should not be restricted by age-based barriers when patients meet clinical criteria. They argue that restricting such treatments leads to worse mental health outcomes and higher rates of self-harm among transgender youth who cannot access support.
What the Numbers Show
The Oregon study examined claims covering approximately 80 percent of insured youth in the state, making it one of the most comprehensive analyses of pediatric gender medicine utilization available for a U.S. population. The data show treatment rates increased substantially over the seven-year period studied.
Key figures from the research: One in 240 girls (approximately 0.42 percent) was taking testosterone by age 17. Approximately one in 630 boys (roughly 0.16 percent) was taking estrogen by age 17. Across all ages, about 1 percent of insured youth had received a gender-related diagnosis; for females the rate reached 1.5 percent.
The study period ran from 2016 to 2023, capturing both pre-pandemic and post-pandemic utilization patterns. Researchers noted that Oregon's supportive legal environment—including laws prohibiting discrimination based on gender identity—may have contributed to higher rates compared to states with more restrictive policies.
The Bottom Line
The Oregon findings offer one of the most detailed snapshots available of pediatric gender medicine utilization in a permissive policy environment, though they represent a single state and cannot be generalized nationwide. The debate over interpretation is likely to intensify as more states collect similar data under varying legal frameworks.
Policymakers in several Republican-controlled states have cited rising treatment rates as justification for age restrictions or outright bans on pediatric gender medicine, while Democratic-led states have moved to protect access. Congress has not enacted federal restrictions, leaving policy fragmented across state lines.
What remains unclear is whether the Oregon figures represent a ceiling driven by remaining barriers, a floor reflecting adequate access, or something in between. Researchers studying these questions say long-term follow-up data on psychological outcomes—not just utilization rates—will be necessary to assess whether expanded access produces net benefits for adolescent patients.